The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

Pfizer (PFE) stock in focus as the company with Astellas Pharma (ALPMF) (ALPMY) announce a Phase 3 trial win for their ...

Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

The segment was heavily boosted by the Seagen acquisition back in 2023, that has the potential to become a high-growth area for Pfizer.

Investing.com - UBS initiated coverage on 3SBio Inc (HK: 1530) (OTC:TRSBF) with a Buy rating and a price target of HK$30.00 on Friday. The pharmaceutical company, which focuses on haematology and ...

UBS views this record-making agreement as validation of 3SBio’s research and development capabilities, noting potential upside in SSGJ-707’s overseas peak sales and value from other pipeline ...

Investing.com - UBS initiated coverage on 3SBio Inc (HK: 1530) (OTC:TRSBF) with a Buy rating and a price target of HK$30.00 on Friday. The pharmaceutical company, which focuses on haematology and ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Pfizer's hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain types of antibodies, the U.S. drugmaker said on Thursday.

NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company’s common stock, payable September 2 ...

Pfizer Inc. has initiated a new clinical study titled A Phase 1, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and ...

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...